• The company announced a significant regulatory update, with the FDA granting its appeal following a Formal Dispute Resolution process, paving the way for a Biologics License Application (BLA) resubmission for ONS-5010/LYTENAVA™ in June 2026.
  • Ascendiant Capital maintained a Buy rating on the stock and significantly raised its price target from $6.00 to $10.00.
  • Upward momentum is further supported by a broad risk-on market environment, with major U.S. equity futures gaining over 1%.